This
report provides an overview of the emerging market
for cancer vaccines and measures their potential
impact on a number of cancer markets. Vaccine product
candidates are discussed within the context of the
disease areas they are attempting to penetrate and
include: melanoma, prostate cancer, colorectal cancer,
lung cancer, breast cancer, and pancreatic cancer.
There are currently over twenty Phase III trials
ongoing for various indications and new approvals
may come as early as 2005.
The
value of the market for cancer vaccines has the
potential to reach $6 billion by 2010. This report
is designed to provide the information, insight
and analysis key to an understanding of how cancer
vaccines will impact the biotech and pharmaceutical
marketplace. Those in the field of cancer therapy
and cancer vaccines will want to read this report
in order to better understand where and how vaccines
will make a difference in future cancer therapy.
This
232-page report:
-
Gauges
the potential of key vaccine products nearing
commercialization.
-
Analyzes
the results of key clinical trials as a means
of determining future success in the market.
-
Forecasts
financial growth of the cancer vaccine market
through 2010. Assesses the competition from cytotoxics
and other biologics in six key cancer markets.
-
Provides
valuable data concerning patient populations,
survival rates, and global epidemiology Identifies
and discusses trends and issues that will have
a significant impact on the cancer vaccine market.
-
Profiles
the leading companies in the field and provides
valuable information and analysis concerning their
lead vaccine candidates.
|
